Viz.ai — Valuation, Funding & Investors

Viz.ai builds an AI-powered care coordination platform used by hospitals to speed diagnosis and treatment, running more than 50 FDA-cleared algorithms that analyze CT scans, EKGs and echocardiograms in real time. Its Viz Cardio suite targets cardiovascular care, and through Viz Life Sciences the company partners with pharmaceutical and medical device makers to build customized care pathways for treatable diseases.

Neurosurgeon Chris Mansi and machine-learning researcher David Golan founded Viz.ai in 2016 after a patient underwent successful brain surgery but died because of preventable delays in her care. The platform has been deployed in more than 2,000 hospitals, and it flags conditions such as large vessel occlusion strokes to clinicians in real time.

Listed funds carry late-stage private names. A fund's latest schedule of investments shows whether it holds Viz.ai.

Often trade at a premium or discount to NAV.

Platforms match existing holders with buyers. Viz.ai availability at any moment is set by the holders.

High minimums, transfer approval, company right-of-first-refusal.

Valuations, rounds and IPO status for every company in the directory — Viz.ai included.

Viz.ai builds an AI-powered care coordination platform used by hospitals to speed diagnosis and treatment, running more than 50 FDA-cleared algorithms that analyze CT scans, EKGs and echocardiograms in real time.

Viz.ai is private, so its shares are not available on public markets.

Viz.ai operates in Artificial Intelligence.

Viz.ai's headquarters is in San Francisco, California.

Viz.ai has about 328 employees.